	US 12,012,453 B2
	Methods for treating late-stage small cell lung cancer by administering a human anti-PD-L1 antibody, an etoposide and a platinum-based therapeutic
Haiyi Jiang, Gaithersburg, MD (US); Yifan Huang, Gaithersburg, MD (US); Phillip Dennis, Gaithersburg, MD (US); Norah Shire, Gaithersburg, MD (US); and Jon Armstrong, Cambridge (GB)
Assigned to ASTRAZENECA AB, Sodertalje (SE)
Filed by ASTRAZENECA AB, Sodertalje (SE)
Filed on Sep. 4, 2020, as Appl. No. 17/012,643.
Claims priority of provisional application 62/896,224, filed on Sep. 5, 2019.
Prior Publication US 2021/0070863 A1, Mar. 11, 2021
Int. Cl. C07K 16/28 (2006.01); A61K 9/00 (2006.01); A61K 31/555 (2006.01); A61K 31/7048 (2006.01); A61K 33/243 (2019.01); A61P 35/00 (2006.01)

CPC C07K 16/2827 (2013.01) [A61K 9/0019 (2013.01); A61K 31/555 (2013.01); A61K 31/7048 (2013.01); A61K 33/243 (2019.01); A61P 35/00 (2018.01); C07K 16/2818 (2013.01)]

48 Claims

1. A method of extending progression-free survival (PFS) in a patient with extensive-stage small cell lung cancer (ES-SCLC), comprising:

treating the patient with up to four cycles of

i) a human anti-PD-L1 antibody, wherein the anti-PD-L1 antibody comprises durvalumab, and

ii) an etoposide and a platinum-based therapeutic agent (EP);

wherein the anti-PD-L1 antibody and EP are administered every three weeks (Q3W) followed by a maintenance phase wherein the anti-PD-L1 antibody is administered every four weeks (Q4W).